The High-Tech CEO : How to Lead R&D When You're Not the Expert book cover
1st Edition

The High-Tech CEO
How to Lead R&D When You're Not the Expert

ISBN 9780367695804
Published February 8, 2022 by Routledge
130 Pages 4 B/W Illustrations

FREE Standard Shipping
USD $42.95

Prices & shipping based on shipping country


Book Description

This book examines the impact of CEOs on firm performance and focuses on their role in science-based innovation to answer the question, is it possible to lead highly complex R&D projects and innovation that you do not understand?

Today, science and technology move so fast that even managers of R&D teams can become quickly disconnected from new developments. Similarly, business leaders may be required to lead organisations with technical knowledge beyond their own expertise. How to manage teams and retain respect and influence is a recognised challenge. Filled with insight from managers and CEOs in science and technology organisations, the book unlocks the skills required to balance the leadership and managerial needs of the organisation, motivate the technical teams and drive successful innovation in new product development environments. Due to the vital role played by experts in a chosen field of technical and scientific expertise, the book also describes what these specialists need and expect from their leaders.

The book is required reading for managers in high tech and scientific environments – the CEO, CSO and the R&D manager. It can also be used as a classroom reference book on the management skills required for leading high-tech projects.

Table of Contents

1. Introduction – A Valid Question 2. CEOs and Firm Performance 3. CEOs and Innovation 4. CEOs and Science-Based Innovation 5. CEO Absorptive Capacity

View More



Jan Rosier is the ELAN Professor of the Business of Biotechnology at UCD. He holds both a doctorate in pharmaceutical sciences (Ghent University, Belgium) and a doctorate in management (Cranfield School of Management, UK). Prior to his academic appointment, he was instrumental in the development of several new breakthrough drugs and was CEO of a start-up high-tech firm.